Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 60,647 | 9,216 | 4,695 | 1,064 | 0 |
| Gross Profit | 60,647 | 9,216 | 4,695 | 1,064 | N/A |
| Operating Expenses | 47,643 | 35,743 | 37,337 | 36,011 | 34,863 |
| Operating Income | 13,004 | -26,527 | -32,642 | -34,947 | -34,863 |
| Other Income | 2,597 | 2,739 | 2,584 | 3,062 | 1,589 |
| Pre-tax Income | 15,601 | -23,788 | -30,058 | -31,885 | -33,274 |
| Income Tax | 2,164 | 71 | 252 | 83 | -22 |
| Net Income Continuous | 13,437 | -23,859 | -30,310 | -31,968 | -33,252 |
| Net Income | $13,437 | $-23,859 | $-30,310 | $-31,968 | $-33,252 |
| EPS Basic Total Ops | 0.27 | -0.29 | -0.43 | -0.53 | -0.57 |
| EPS Basic Continuous Ops | 0.26 | -0.29 | -0.43 | -0.53 | -0.57 |
| EPS Diluted Total Ops | 0.27 | -0.29 | -0.43 | -0.53 | -0.57 |
| EPS Diluted Continuous Ops | 0.26 | -0.29 | -0.43 | -0.53 | -0.57 |
| EPS Diluted Before Non-Recurring Items | 0.23 | -0.29 | -0.43 | N/A | N/A |
| EBITDA(a) | $15,065 | $-24,424 | $-30,582 | $-33,050 | $-33,017 |